Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-05-25

Clinical Trial Update: Avelumab in Patients With Newly Diagnosed Glioblastoma Multiforme [Phase 2]

View source ↗

Summary

A phase 2 trial of the anti-PD-L1 agent avelumab in newly diagnosed glioblastoma multiforme has completed enrollment and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Avelumab (avelumab)

Snippet

Sponsor: Clinique Neuro-Outaouais | Conditions: Glioblastoma Multiforme of Brain | Phase 2 | Status: COMPLETED | Results posted: 2025-05-25